ALS emerges as a second-derivative gold play with a quality industrial wrapper

A surge in junior miner exploration spending, driven by high gold and copper prices, has flowed straight through to ALS Ltd's minerals testing volumes, giving fund managers a rare combination of cyclical leverage and quality-industrial consistency that has driven the stock to all-time highs.

30 Jun 2026 · 6 min read

ALS Ltd (ASX: ALQ) has become one of the clearest examples of a business benefiting from the gold and copper price boom without carrying the direct commodity price and cost inflation risk of an actual miner. Wilson Asset Management set out the operational foundation in July 2025, describing ALS as a global leader in testing, inspection, certification and verification services across commodities and life sciences, delivering a robust first-quarter FY2026 update that reaffirmed guidance for 5-7% organic revenue growth and margin expansion, with digitisation and AI flagged as medium-term drivers of further margin uplift.

A second-derivative play on the gold price

Airlie Funds Management articulated the core investment case most precisely in January 2026, describing ALS as a second-derivative play on the gold price, given roughly half its earnings come from commodities testing driven mostly by gold and copper exploration, with those testing volumes dropping through at very high incremental margins. The fund contrasted this favourably with owning gold miners directly, which face significant cost-based inflation and are, in its view, imperfect vehicles for expressing a positive view on the gold price.

It's sort of the opposite for gold miners, who face a lot of cost-based inflation and are pretty imperfect vehicles to play a positive view on the gold price... Half of their earnings come from commodities testing. Most of that's driven by gold and copper exploration.

Airlie Funds Management, Webinar, January 2026

Junior miner capital raisings flow straight through

The mechanism behind ALS's earnings leverage is straightforward. Antares Capital explained in October 2025 that strength in gold prices, alongside related minerals such as copper, had driven a raft of capital raisings by junior miners seeking exploration funding, with much of that capital ultimately flowing to ALS as the major laboratory for measuring mining assays. Oracle Advisory Group added ALS to its portfolio in December 2025 specifically to increase its exposure to the materials sector broadly and underlying commodities specifically, treating the stock as a way to access the sector without direct commodity price exposure.

A diversified, quality industrial underneath the cyclical leverage

Beyond the pure gold-cycle leverage, several managers point to ALS's diversification as a source of consistency uncommon among cyclical industrials. Blackwattle Investment Partners highlighted management's capital deployment over the past 10 to 15 years, expanding into life sciences, environmental testing and pharma testing to reduce reliance on metallurgical testing alone, arguing this diversification has driven mid-to-high single-digit revenue growth layered with successful M&A, producing returns that have outperformed mid-cap indices by more than 50% since COVID. Pendal Group, also a buyer, said it was strongly predisposed to the existing minerals services management team given the positive changes made under new leadership over the past three to four years, describing the current gold price environment as the biggest attraction given how much capital gold companies are deploying into exploration and new mine builds.

That consistency, which we seek in quality businesses, drives compounding returns for shareholders... the consistency of returns has been enormous, outperforming mid-cap indices by over 50% since COVID.

Blackwattle Investment Partners, Article, October 2025

The valuation has stretched to all-time highs

The strength of the thesis has been reflected fully in the multiple. Pendal Group noted in November 2025 that ALS's result was in line with FY25 expectations and slightly ahead of FY26 guidance, but the market's expectations had been running high, and the stock had re-rated to all-time highs above 26 times price-to-earnings, breaking out relative to its historical trading ranges against global peers. The fund noted consensus already prices in 6-8% annual revenue growth and 50-100 basis points of annual margin expansion through FY27/28, with 10-15% EPS growth largely already reflected in the share price, even as it flagged a more bullish commodities cycle or life sciences recovery as offering further upside risk beyond consensus.

What managers are watching next

With ALS trading at valuation levels that already embed a substantial earnings growth expectation, the catalysts fund managers are tracking are whether the gold and copper exploration cycle continues to drive junior miner capital raisings at the current pace, whether life sciences end markets recover to offset any moderation in commodities testing growth, and whether management can continue layering earnings-accretive acquisitions onto the existing diversified platform to sustain the compounding return profile that has driven the stock's outperformance.